Welcome to Paid Research Studies


Browse Locations ... United States» ... Minnesota» ... Burnsville






  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Neurofibrosarcoma;   Chondrosarcoma;   Endometrial Stromal Sarcoma;   Mast Cell Sarcoma;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Ovarian Carcinosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: alisertib;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Lymphedema;   Sexuality and Reproductive Issues;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer
    Interventions:   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Procedure: cone biopsy;   Procedure: loop electrosurgical excision procedure
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
    Interventions:   Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
    Interventions:   Biological: trebananib;   Other: placebo;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
    Interventions:   Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: methotrexate;   Procedure: quality-of-life assessment
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
    Interventions:   Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
    Interventions:   Dietary Supplement: cholecalciferol;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
    Interventions:   Drug: temsirolimus;   Biological: bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
    Interventions:   Drug: sorafenib tosylate;   Other: placebo;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: cisplatin;   Drug: mitomycin C
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014